相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer
Bo Gong et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study
Yutaka Fujiwara et al.
Oncotarget (2018)
Recent Advances in Targeting ROS1 in Lung Cancer
Jessica J. Lin et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2017)
Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers
Miho J. Fuse et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Targeting TRK family proteins in cancer
Yekaterina B. Khotskaya et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon et al.
CANCER DISCOVERY (2017)
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer
Alexander Drilon et al.
CLINICAL CANCER RESEARCH (2016)
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
Mariangela Russo et al.
CANCER DISCOVERY (2016)
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
A. Drilon et al.
ANNALS OF ONCOLOGY (2016)
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
Ryohei Katayama et al.
EBIOMEDICINE (2016)
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
Helen Y. Zou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
Robert C. Doebele et al.
CANCER DISCOVERY (2015)
Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion-Positive Cancer
Ryohei Katayama et al.
CLINICAL CANCER RESEARCH (2015)
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Acquired Resistance to Crizotinib from a Mutation in CD74-ROS1
Mark M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Tyrosine kinase gene rearrangements in epithelial malignancies
Alice T. Shaw et al.
NATURE REVIEWS CANCER (2013)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802
Edward G. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
RET, ROS1 and ALK fusions in lung cancer
Kengo Takeuchi et al.
NATURE MEDICINE (2012)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al.
CELL (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
R Sordella et al.
SCIENCE (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
分享论文
